Low T (testosterone for you) = High R2 ([R]evenue for drug companies and [R]isk for you)
I can still remember seeing the first of what became on onslaught of television commercials asking if viewers suffered from “Low T”. I didn’t have any idea what that even meant, but the marketers were clever. Who would want to admit they had has less than a manly dose of testosterone? Uh, nobody. But “Low T?” That’s a medical term than has nothing to do with my manhood, thought the marketers. And it worked, men signed up and filled over 400,000,000 prescriptions for the innocuously advertised “Low T” drugs for their low libido, fatigue, irritability or muscle loss, and now they should be aware of the heart-related risks of testosterone therapy. And that’s not just “call us” talk from our law firm, that’s according to a statement from the Endocrine Society.
Drug companies touted testosterone as a near panacea for such conditions. But the U.S. Food and Drug Administration (FDA) has approved testosterone products only for hypogonadism, when the testicles do not produce enough testosterone. Testosterone isn’t approved for age-related conditions and age-related decline in testosterone levels which a large number of people were taking them for. Testosterone levels naturally begin to decline after age 30.
That “Low T” sales pitch worked! The testosterone market was valued between $18 and $20 million in 1988, and was worth about $2.2 billion in 2013. Low T = High R (revenue!)
If you or a loved one suffered a stroke, heart attack, or death while on Low T therapy, call one of our testosterone attorneys for a free case review.